News
Omnio raises €4.3 Million to accelerate wound-healing drug to clinical stage
SWEDEN, 10th May, 2025 — Omnio AB, a Umeå-based biotech company focused on innovative treatments for chronic wounds, has secured a major capital injection from current shareholders. “This support allows us to complete our GMP manufacturing process and move toward clinical trials,” says newly appointed CEO,...
- Business
Omnio is preparing for taking the company to the next phase
SWEDEN, 5th May, 2023 — Omnio AB, a private biopharmaceutical company developing recombinant plasminogen for chronic non-healing wounds, announces the inauguration of a new board of directors that brings together an outstanding team of seasoned executives in the biotech and life sciences industries. The board of...
- Funding
Omnio raises 1.5M EUR in successful series A funding
SWEDEN, 8th November, 2022 — Omnio AB, a private biopharmaceutical company developing recombinant plasminogen to heal chronic wounds announces a successful 1.5M EUR funding round. The funds will be allocated to develop a manufacturing process for the recombinant plasminogen drug product and conduct efficacy studies of...
- Funding
Omnio AB raises 5.5MSEK in fundraising round
SWEDEN, 6th December, 2021 — Omnio AB is developing new drug products based on the proinflammatory and immune regulatory effects of the serum protein plasminogen. During fall the company successfully raised 5.5MSEK in a new share issue and welcomed four new investors to the company. The...
